In India #Bharat #Biotech and #Zydus #Cadila are the two pharmaceutical companies who are in the race for developing the first locally-made vaccine to fight Novel Coronavirus. Both these companies are using human subjects for trials in six cities of different states. On 24th July, a 30-year-old man from Delhi became the first person from his city to be administered an intramuscular injection (0.5ml) of Bharat Biotech (BB) Covaxin at AIIMS.
On July 15th, the first doses of vaccine were administered to the volunteers by both Zydus and BB after getting permission for Phase I and II clinical trials.
In India, the vaccine candidate developed by Oxford University will be tested soon after receiving regulatory approval. Serum India is working in partnership with UK’s Astra Zeneca on that vaccine.
BB’s Covaxin which has been developed in collaboration with National Institute of Virology (NIV) and Indian Council of Medical Research (ICMR) will be sent for trials in 12 hospitals e.g. PGI Rohtak, AIIMS Patna and Delhi – in 12 cities. 500 healthy and medically fit volunteers having no comorbidities aged between 18 and 55 will be involved in the testing. On the other hand testing of ZyCoV-D vaccine candidate developed by Zydus Cadila is yet to be extended to other cities from its research centre in Ahmedabad.
The 30-year-old volunteer from Delhi after being administered BB’s Covaxin was kept under observation for two hours and later sent back home as he showed no abrupt side effects. He will be called back after two days for re-examination. The minor allergic reactions generally observed among volunteers after administering the vaccine were those of pain, mild fever and skin reddening. Apart from these mild reactions no other health issues came up among the subjects.
Covaxin testing trials will be started in #Bhubaneshwar, #Belgaum, #Vizag, #Goa, #Gorakhpur, #Kanpur and #Nagpur. In #Kanchipuram, #New Delhi, #Rohtak, #Patna and #Hyderabad the trials have already begun.
In Phase I, the right dosage of vaccine effective in fighting the virus will be decided after the safety of vaccine is studied in a healthy subject. Based on the data analysis of the ongoing Phase I trials, the course of Phase II clinical trials will be decided.